



## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

REC'D	1	1	JUN	2004
WIPO				PCT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference	FOR FURTHER ACTION	See Notification	n of Transmittal of International camination Report (Form PCT/IPEA/416)
1242/ 57 PCT	International filing date (day/m	onth/vear)	Priority date (day/month/year)
International application No.		,	
PCT/US03/25015	08 August 2003 (08.08.2003)		08 August 2002 (08.08.2002)
International Patent Classification (IPC)	or national classification and IPC	3	
IPC(7): A61K 31/40, 31/535, 31/35 and	US Cl.: 514/418, 233.5, 453		
Applicant			
VANDERBILT UNIVERSITY			
1 This international realimi	is transmitted to the applicant	t according to A	
This report is also ac	ecompanied by ANNEXES, i. nended and are the basis for the y (see Rule 70.16 and Section	in PANATE STAINE	description, claims and/or drawings sheets containing rectifications made inistrative Instructions under the PCT).
3. This report contains indic	cations relating to the following	ng items:	
I Basis of the re	port		
II Priority			
	ment of report with regard to	novelty, inventiv	e step and industrial applicability
IV Lack of unity			9
V ! Reasoned state applicability;	ement under Article 35(2) wit citations and explanations sup	h regard to nove porting such stat	Ity, inventive step or industrial ement
VI Certain docum	ments cited		
VII Certain defec	ts in the international applicati	ion ,	
VIII Certain obser	vations on the international ap	plication	
	·		
Date of submission of the demand		Date of completion	on of this report
15 January 2004 (15.01.2004)	1	0 May 2004 (10.0	5.2004)
Name and mailing address of the IPE.	A/US A	uthorized officer	
Mail Stop PCT, Attn: IPEA/US	3	Dahasa Gaale	7. Roberts for
Commissioner for Patents P.O. Box 1450		Redecca Cook	y. 100 - 901
Alexandria, Virginia 22313-145 Facsimile No. (703) 872-9306	50	Telephone No. (5	71) 272-1600 <i>V</i>
	1008)		

Form PCT/IPEA/409 (cover sheet)(July 1998)

INTERNATIONAL	DDET DATE	TOWARDNIA TOTON	DEPORT
INTERNATIONAL	PRELIMINATION	EXAMINATION	KEIOKI

International app	
PCT/US03/25015	

I.	Basis	of the report	
1.	With	regard to the elements of the international application:*	
	$\boxtimes$	the international application as originally filed.	
		the description:	
		pages 1-72 as originally filed	
		pages NONE , filed with the demand pages NONE , filed with the letter of	i
	$\boxtimes$	the claims:	
		pages 73-76 , as originally filed pages NONE , as amended (together with any statement) under Article 19	ĺ
		pages NONE, filed with the demand	ĺ
		pages NONE, filed with the letter of	ĺ
	$\boxtimes$	the drawings:	
		pages NONE, as originally filed	ĺ
		pages NONE, filed with the demand pages NONE, filed with the letter of	i
			l
	$\boxtimes$	the sequence listing part of the description:	
		pages NONE, as originally filed pages NONE, filed with the demand	
		pages NONE filed with the letter of	١
2	. Witl	b regard to the language all the elements marked above were available or furnished to this Authority in the	l
	1000	wage in which the international application was filed. Unless otherwise indicated under this item.	١
	The	se elements were available or furnished to this Authority in the following language which is:	
		the language of a translation furnished for the purposes of international search (under Rule23.1(b)).	1.
		the language of publication of the international application (under Rule 48.3(b)).	
		the language of the translation furnished for the purposes of international preliminary examination(under Rules	
		55.2 and/or 55.3).	
3	. Wit	th regard to any nucleotide and/or amino acid sequence disclosed in the international application, the mational preliminary examination was carried out on the basis of the sequence listing:	l
ŀ	inte		l
	닏	contained in the international application in printed form.	1
		filed together with the international application in computer readable form.	١
		furnished subsequently to this Authority in written form.	١
		furnished subsequently to this Authority in computer readable form.	۱
		The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the	١
		international application as filed has been furnished.	1
		The statement that the information recorded in computer readable form is identical to the written sequence listing	밁
		has been furnished.	
4	1. 🛛	The amendments have resulted in the cancellation of:	1
1		the description, pages NONE	-
1			ļ
1		the claims, Nos. NONE.	
1		the drawings, sheets/fig NONE	
	5	This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**	n
	thin was	lacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to lacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to lacement sheets which have been furnished to the report since they do not contain amendments (Rules 70.16 and 70.17).	
	** Any	replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.	

International appli	No.
Illicitudiculus appro	210.
PCT/US03/25015	
101/0003/2010	

Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applical citations and explanations supporting such statement  STATEMENT  Novelty (N)  Claims  Inventive Step (IS)  Claims  Claims  Claims  Claims  NONE  Industrial Applicability (IA)  Claims  Claims  NONE  Lindustrial Applicability (IA)  Claims  Claims  Claims  1-46  Claims  NONE  Claims 1-46  Claims  Claims 1-46 meet the criteria seto out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest a met reating a tumor by administering a P13k antagonist and treating the tumor with ionizing radiation.  Claims 1-46 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter can be made or used in industry.	
Novelty (N)  Claims 1-46 Claims NONE  Inventive Step (IS)  Claims 1-46 Claims NONE  Industrial Applicability (IA)  Claims 1-46 Claims NONE  Claims 1-46 Claims 1-46 Claims NONE  Claims 1-46 NONE  Claims 1-46 meet the criteria seto cut in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest a met creating a tumor by administering a P13k antagonist and treating the tumor with ionizing radiation.  Claims 1-46 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter can be made or used in industry.	ility; 
Inventive Step (IS)  Claims 1-46 Claims NONE  Industrial Applicability (IA)  Claims 1-46 Claims NONE  Industrial Applicability (IA)  Claims 1-46 Claims 1-46 NONE  2. CITATIONS AND EXPLANATIONS Claims 1-46 meet the criteria seto out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest a met recating a tumor by administering a P13k antagonist and treating the tumor with ionizing radiation.  Claims 1-46 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter can be made or used in industry.	
Inventive Step (IS)  Claims 1-46 Claims NONE  Industrial Applicability (IA)  Claims 1-46 Claims NONE  Industrial Applicability (IA)  Claims NONE  Claims NONE  Claims NONE  Claims 1-46 Claims NONE  Claims NONE	YES
Industrial Applicability (IA)  Claims  Claims  1-46  NONE  CITATIONS AND EXPLANATIONS  Claims 1-46 meet the criteria seto out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest a met reating a tumor by administering a P13k antagonist and treating the tumor with ionizing radiation.  Claims 1-46 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter an be made or used in industry.	NO
Claims NONE  Industrial Applicability (IA)  Claims 1-46  Claims NONE  CITATIONS AND EXPLANATIONS  Claims 1-46 meet the criteria seto cut in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest a met reating a tumor by administering a P13k antagonist and treating the tumor with ionizing radiation.  Claims 1-46 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter an be made or used in industry.	YBS
Industrial Applicability (IA)  Claims  1-46  Claims  NONE  CITATIONS AND EXPLANATIONS  laims 1-46 meet the criteria seto out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest a met eating a tumor by administering a P13k antagonist and treating the tumor with ionizing radiation.  Claims 1-46 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter an be made or used in industry.	NO
CITATIONS AND EXPLANATIONS  laims 1-46 meet the criteria seto cut in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest a met eating a turnor by administering a P13k antagonist and treating the turnor with ionizing radiation.  claims 1-46 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter an be made or used in industry.	
CITATIONS AND EXPLANATIONS  laims 1-46 meet the criteria seto cut in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest a met eating a turnor by administering a P13k antagonist and treating the turnor with ionizing radiation.  claims 1-46 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter an be made or used in industry.	YEŞ
CITATIONS AND EXPLANATIONS  Taims 1-46 meet the criteria seto cut in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest a met reating a tumor by administering a P13k antagonist and treating the tumor with ionizing radiation.  Taims 1-46 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter an be made or used in industry.	NO
laims 1-46 meet the criteria seto cut in PCT Article 33(2)-(3), because the prior at cut-of start of the cating a tumor by administering a P13k antagonist and treating the tumor with ionizing radiation.  claims 1-46 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter an be made or used in industry.	
an be made or used in industry.	
	Claimed
	-

Form PCT/IPEA/409 (Box V) (July 1998)